1-(2-chloro-4-((2-chloroethyl)amino)-phenyl)-5-(trifluoromethyl)pyridin-2(1H)-one | 1256700-79-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(2-chloro-4-((2-chloroethyl)amino)-phenyl)-5-(trifluoromethyl)pyridin-2(1H)-one
• 英文别名: 1-[2-Chloro-4-(2-chloroethylamino)phenyl]-5-(trifluoromethyl)pyridin-2-one
• CAS: 1256700-79-4
• 化学式: C₁₄H₁₁Cl₂F₃N₂O
• 分子量: 351.155
• InChiKey: SSPNTMUSBIELCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  哌嗪 、 1-(2-chloro-4-((2-chloroethyl)amino)-phenyl)-5-(trifluoromethyl)pyridin-2(1H)-one 在 sodium iodide 作用下， 以 乙腈 为溶剂， 反应 12.0h， 生成 1-(2-chloro-4-((2-(piperazin-1-yl)ethyl)amino)phenyl)-5-(trifluoromethyl)pyridin-2(1H)-one
  参考文献：
  名称：

  Preparation of 1-(substituted aryl)-5-trifluoromethyl-2-(1H)pyridone compounds and salts thereof and their applications

  摘要：

  公开号：

  EP2436670B1
• 作为产物：
  描述：

  2-羟基-5-三氟甲基吡啶 在 盐酸 、 氯化亚砜 、 铁粉 、 potassium carbonate 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 正丁醇 为溶剂， 反应 28.0h， 生成 1-(2-chloro-4-((2-chloroethyl)amino)-phenyl)-5-(trifluoromethyl)pyridin-2(1H)-one
  参考文献：
  名称：

  Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy

  摘要：

  Oxidative stress, inflammation and fibrosis can cause irreversible damage on cell structure and function of kidney and are key pathological factors in Diabetic Nephropathy (DN). Therefore, multi-target agents are urgently need for the clinical treatment of DN. Using Pirfenidone as a lead compound and based on the previous research, two novel series (5-trifluoromethyl)-2(1H)-pyridone analogs were designed and synthesized. SAR of (5-trifluoromethyl)-2(1H)-pyridone derivatives containing nitrogen heterocyclic ring have been established for in vitro potency. In addition, compound 8, a novel agent that act on multiple targets of anti-DN with IC50 of 90 mu M in NIH3T3 cell lines, t(1/2) of 4.89 +/- 1.33 h in male rats and LD50 > 2000 mg/kg in mice, has been advanced to preclinical studies as an oral treatment for DN. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.07.001

文献信息

• ANTI-FIBROTIC PYRIDINONES
  申请人：InterMune, Inc.

  公开号：US20140107110A1

  公开（公告）日：2014-04-17

  Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.

  本发明涉及吡啶酮化合物、制备这些化合物的方法以及治疗纤维化疾病的方法。
• Anti-fibrotic pyridinones
  申请人：InterMune, Inc.

  公开号：US10233195B2

  公开（公告）日：2019-03-19

  Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.

  本发明公开了吡啶酮化合物、制备这些化合物的方法以及治疗纤维化疾病的方法。
• [EN] ANTI-FIBROTIC PYRIDINONES<br/>[FR] PYRIDINONES ANTI-FIBROTIQUES
  申请人：INTERMUNE INC

  公开号：WO2015153683A8

  公开（公告）日：2016-10-13
• PREPARATION OF 1-(SUBSTITUTED ARYL)-5-TRIFLUOROMETHYL-2-(1H)PYRIDONE COMPOUNDS AND SALTS THEREOF AND THEIR APPLICATIONS
  申请人：Hu Gaoyun

  公开号：US20120142688A1

  公开（公告）日：2012-06-07

  A 1-(substituted aryl)-5-trifluoromethyl-2-(1H)pyridone compounds and pharmaceutical acceptable salts, preparation methods and uses for preparing the drugs for treating fibrosis thereof.
• Anti-Fibrotic Pyridinones
  申请人：INTERMUNE, INC.

  公开号：US20190321343A1

  公开（公告）日：2019-10-24

  Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.